`SALES AT EX-MANUFACTURER PRICE
`U.S. DOLLARS BY PRODUCT, INCLUDING GENERICS
`Q4 2012 – Q3 2014
`
`2012
`
`Q4
`
`Q1
`
`Q2
`
`Q3
`
`Q4
`
`Q1
`
`2013
`
`2014
`
`Q2
`
`Q3
`
`Total
`
`$15,861,022
`
`$34,208,377
`$31,138,049
`$181,756,871
`
`
`
`$14,435,723
`$14,328,948
`$43,543,924
`$29,985,339
`$176,843,700
`
`$13,488,772
`$63,999,957
`$49,544,835
`$26,126,981
`$188,358,662
`
`
`
`$12,738,028
`$78,256,141
`$52,681,394
`$24,222,882
`$188,073,550
`
`
`
`$10,995,764
`$82,852,340
`$88,655,837
`$22,848,420
`$198,774,706
`
`
`
`$10,862,442
`$84,350,865
`$125,234,464
`$22,965,409
`$206,471,379
`
`
`
`$10,716,791
`$78,062,725
`$142,152,239
`$22,052,298
`$175,172,388
`
`
`
`$10,462,288
`$77,866,869
`$157,678,111
`$22,614,230
`$163,851,048
`
`
`
`$99,560,830
`$479,717,845
`$693,699,181
`$201,953,608
`$1,479,302,304
`
`
`
`$262,964,319
`
`$279,137,634
`
`$341,519,207
`
`$355,971,995
`
`$404,127,067
`
`$449,884,559
`
`$428,156,441
`
`$432,472,546
`
`$2,954,233,768
`
`6.0%
`
`13.0%
`11.8%
`69.1%
`
`
`
`5.2%
`5.1%
`15.6%
`10.7%
`63.4%
`
`
`
`3.9%
`18.7%
`14.5%
`7.7%
`55.2%
`
`
`
`3.6%
`22.0%
`14.8%
`6.8%
`52.8%
`
`
`
`2.7%
`20.5%
`21.9%
`5.7%
`49.2%
`
`
`
`2.4%
`18.7%
`27.8%
`5.1%
`45.9%
`
`
`
`2.5%
`18.2%
`33.2%
`5.2%
`40.9%
`
`
`
`2.4%
`18.0%
`36.5%
`5.2%
`37.9%
`
`
`
`3.4%
`16.2%
`23.5%
`6.8%
`50.1%
`
`100.0%
`
`100.0%
`
`100.0%
`
`100.0%
`
`100.0%
`
`100.0%
`
`100.0%
`
`100.0%
`
`100.0%
`
`Ixempra®
`Kadcyla®
`Perjeta®
`Tykerb®
`Xeloda®
`
`Total
`
`Ixempra®
`Kadcyla®
`Perjeta®
`Tykerb®
`Xeloda®
`
`Total
`
`
`
`
`
`
`
`
`
`Notes & Sources:
`¹ Excludes Herceptin®.
`Kadcyla® is indicated as a single agent for the treatment of people with HER2-positive metastatic breast cancer who have received prior treatment with Herceptin® and a taxane
`chemotherapy. See, e.g., Exhibit 2317. In contrast:
`Xeloda® can be used to treat colon, rectal, and other cancers. See, e.g., Exhibit 2246.
`Perjeta® received FDA approval for neoadjuvant breast cancer therapy. See, e.g., Exhibit 2211.
`Tykerb® is used to treat breast cancer, but is prescribed with a second medicine (Xeloda® or Femara®). See, e.g., Exhibit 2342.
`(These assertions and sources can be found in the report.)
`Includes brand and generic values.
`Ixempra® includes brand IXEMPRA 10/2007 BM0, identified in field 'Product.'
`Kadcyla® includes brand KADCYLA 02/2013 GTC, identified in field 'Product.'
`Perjeta® includes brand PERJETA 06/2012 GTC, identified in field 'Product.'
`Tykerb® includes brand TYKERB 03/2007 GSK, identified in field 'Product.'
`Xeloda® includes brand XELODA 05/1998 GTC, identified in field 'Product,' and generic capecitabine, identified in field 'Combined Molecule.'
`Includes Xeloda® (capecitabine), which is indicated for use with Tykerb® (lapatinib) in second-line therapy. Excludes other chemotherapeutic agents that may be used to treat breast
`cancer (e.g., vinorelbine), which are indicated for the use of other cancers. See Exhibit 2218 and Exhibit 2343.
`Values reflect field 'Sales $'.
`Percentage calculated as percent of quarterly total.
`Products identified from Exhibit 2103 and Exhibit 2224.
`Data from IMS Health.
`
`IMMUNOGEN 2241, pg. 1
`Phigenix v. Immunogen
`IPR2014-00676
`
`